Free tool
FAERS Monitor: Ocrevus Zunovo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761371 or its brand name (Ocrevus Zunovo, Ocrelizumab and Hyaluronidase-Ocsq). Reports on generic versions are filed under their own applications.
Reports
499
Serious
96
19% of reports
Hospitalization
26
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain66
- injection site erythema53
- fatigue48
- pain40
- no adverse event29
- off label use29
- headache25
- multiple sclerosis relapse25
- rash24
- contusion23
- erythema22
- injection site reaction22
- swelling18
- injection site swelling16
- pruritus14
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2024 | 22 |
| 2025 | 213 |
| 2026 | 262 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,660 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site erythemaSignal | 53 | 18.0 | 14.0 | 839 |
| multiple sclerosis relapseSignal | 25 | 15.4 | 10.5 | 323 |
| injection site reactionSignal | 22 | 13.5 | 9.0 | 243 |
| contusionSignal | 23 | 10.1 | 6.8 | 180 |
| injection site painSignal | 66 | 9.1 | 7.2 | 473 |
| injection site swellingSignal | 16 | 8.8 | 5.4 | 103 |
| swellingSignal | 18 | 8.1 | 5.2 | 106 |
| no adverse eventSignal | 29 | 6.7 | 4.7 | 137 |
| erythemaSignal | 22 | 4.5 | 3.0 | 57 |
| painSignal | 40 | 2.7 | 2.0 | 44 |
| fatigueSignal | 48 | 2.6 | 2.0 | 47 |
| rashSignal | 24 | 2.3 | 1.6 | 17 |
| headache | 25 | 1.7 | 1.1 | 6 |
| pruritus | 14 | 1.5 | 0.9 | 2 |
| off label use | 29 | 1.4 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.